ESCITALOPRAM TEVA-RATIO
As listed in the register: ESCITALOPRAM TEVA-RATIO 15 mg COMPRIMIDOS RECUBIERTOS CON PELICULA EFG
15 mg · comprimido recubierto con película
- Prescription only
- Pain, sleep, mood, epilepsy and the brain
- Active substance
- Escitalopram
- Made by
- Teva Pharma S.L.U.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (escitalopram). It describes the substance, not this Bulgarian product — its uses and doses can differ.
The mechanism of antidepressant action of escitalopram, the S-enantiomer of racemic citalopram, is presumed to be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT).
Escitalopram is metabolized to S-DCT and S-didemethylcitalopram (S-DDCT).
Absorption of escitalopram is not affected by food.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-03-19
Safety of the active substance
This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (escitalopram). It describes the substance, not this Bulgarian product — its uses and doses can differ.
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning.
- Do not use MAOIs intended to treat psychiatric disorders with escitalopram or within 14 days of stopping treatment with escitalopram.
- Do not use escitalopram within 14 days of stopping an MAOI intended to treat psychiatric disorders.
- The use of escitalopram tablets within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated [see Dosage and Administration ( 2.7 ) and Warnings and Precautions ( 5.2 )].
Most commonly observed adverse reactions (incidence ≥ 5% and at least twice the incidence of placebo patients) are: insomnia, ejaculation disorder (primarily ejaculatory delay), nausea, sweating increased, fatigue and somnolence, decreased libido, and anorgasmia ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Torrent Pharma Inc. at 1-800-912-9561, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
Canada13 matching products
Netherlands7 matching products
- Escitalopram 15 mg Teva 15 mg · filmomhulde tablet
- Escitalopram Aurobindo 15 mg 15 mg · filmomhulde tablet
- Escitalopram Bristol 15 mg filmomhulde tabletten 15 mg · filmomhulde tablet
- Escitalopram Polpharma 15 mg orodispergeerbare tabletten 15 mg · orodispergeerbare tablet
- Escitalopram Sandoz 15 mg 15 mg · filmomhulde tablet
- Escitalopram Viatris 15 mg 15 mg · filmomhulde tablet
- Lexapro 15 mg 15 mg · filmomhulde tablet
SwitzerlandNo exact match for this strength and form
Details
| Made by | Teva Pharma S.L.U. |
|---|---|
| Active substance | Escitalopram |
| Used in | Pain, sleep, mood, epilepsy and the brain |
| Strength | 15 mg |
| Form | comprimido recubierto con película |
| Classification | N06AB10 · Pain, sleep, mood, epilepsy and the brain |
| Route | vía oral |
| Marketed | Yes, according to the register |
| Generic | Yes — a generic medicine, according to the register |
| Driving | The regulator flags that this medicine can affect the ability to drive. |
| Name in the register | ESCITALOPRAM TEVA-RATIO 15 mg COMPRIMIDOS RECUBIERTOS CON PELICULA EFG |
| Nº Registro | 74531 |
Source: CIMA — Centro de Información online de Medicamentos · 2026-09-30 · not reviewed by a clinician
Fuente: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), CIMA. Reuse terms: Aviso legal AEMPS.
Other strengths and forms
3 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.